Together, this data confirmed that MYBL2 expression is an important prognostic variable for both OS and DFS patient outcomes, after adjusting for other key clinical factors such as age at diagnosis, tumor (T) stage, and patient smoking history. This evidence concerns the gene MYBL2 and neoplasm.